The 2-year results of the Comparison of AMD Treatment Trials (CATT) show that development of geographic atrophy (GA) was higher in the anti-VEGF monthly dosing group compared to the as-needed group [24]. The gene discussed is VEGFA; the disease is age-related macular degeneration.